Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access
AV Fistula
About this trial
This is an interventional treatment trial for AV Fistula
Eligibility Criteria
Inclusion Criteria:
- Age >18
- Receiving or planning to receive maintenance hemodialysis
- Ability to sign informed consent
- 3 mm venous diameter within recipient vein
Exclusion Criteria:
- History of stroke, transient ischemic attack or intracranial hemorrhage
- History of or high level of suspicion for, severe arterial insufficiency of the hand
- Indication or ongoing therapy with other antiplatelet agents, other than aspirin 81 mg daily
- Indication or ongoing therapy with anticoagulants, including warfarin, low molecular weight heparin, factor Xa inhibitors or direct thrombin and other inhibitors.
Sites / Locations
- Stanford Univeristy
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Vorapaxar intervention
Placebo intervention
This arm will receive the study drug: Vorapaxar sulfate. The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).
This arm will receive the matching placebo. The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm).